Losartan versus ramipril in the treatment of postrenal transplant erythrocytosis

Hortal, L; Fernandez, Armida; Vega, N; Rodríguez, J. Carlos Ruiz; Losada, A. Urrutia; Lorenzo, Marlen N. Castillo; Plaza, C; Palop, L

doi:10.1016/s0041-1345(98)00562-4

Cited by 14 publications

(10 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the ARB losartan has been observed to decrease hemoglobin concentration in the setting of posttransplant erythrocytosis. The pattern of response is similar to that observed with ACE inhibitors 29–31,47 . Alternatively, losartan has been variably associated with the development of anemia in ESRD 48,49 .…”

Section: Renal Failuresupporting

confidence: 64%

“…ACE inhibitor‐ and ARB‐related anemia is a class effect in the CKD population and is independent of dialytic modality, as suggested by findings in both hemodialysis 20–36 and continuous ambulatory peritoneal dialysis patients 38–40 . The exact mechanism(s) of ACE inhibitor‐related anemia in end‐stage renal disease (ESRD) is still argued.…”

Section: Renal Failurementioning

confidence: 99%

“…24,25 the fact that these renin-angiotensin system-blocking agents suppress erythropoiesis is not without some potential benefit. for example, secondary erythropoiesis is not uncommon in a number of situations, including following renal transplantation, 23,24,[26][27][28][29][30][31] prolonged exposure to high altitudes, 32 obesityhypoventilation, 33 and cystic renal disease. 34 in these settings, aCe inhibitors and arbs can be used to good effect in suppressing rbC production.…”

Section: Hemolytic Anemiamentioning

confidence: 99%

“…aCe inhibitor-and arb-related anemia is a class effect in the CKD population and is independent of dialytic modality, as suggested by findings in both hemodialysis [20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36] and continuous ambulatory peritoneal dialysis patients. [38][39][40] in end-stage renal disease (eSrD) is still argued.…”

Section: Renal Failurementioning

confidence: 99%

“…the pattern of response is similar to that observed with aCe inhibitors. [29][30][31]47 alternatively, losartan has been variably associated with the development of anemia in eSrD. 48,49 in particular, the carefully performed studies of Schiffl and Lang 49 suggest that the partial resistance to recombinant erythropoietin, observed with captopril, is not seen with losartan.…”

Section: Renal Failurementioning

confidence: 99%

See 4 more Smart Citations

Antihypertensive Medications and Anemia

Sica

Mannino

2007

J of Clinical Hypertension

View full text Add to dashboard Cite

Antihypertensive medication use can be associated with a reduction in hemoglobin concentration. The magnitude of such a change is generally small, but in certain instances it can be extreme enough to produce a clinically significant degree of anemia. The mechanistic basis for antihypertensive medication-related changes in hemoglobin concentration include hemodilution, hemolytic anemia, and suppression of red blood cell production, as this occurs most commonly with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. A reduction in hemoglobin concentration in a patient who is receiving treatment for hypertension and does not have an obvious source of blood loss should account for potential antihypertensive therapy involvement.

show abstract

Section: Renal Failuresupporting

confidence: 64%

Section: Renal Failurementioning

confidence: 99%

Section: Hemolytic Anemiamentioning

confidence: 99%

Section: Renal Failurementioning

confidence: 99%

Section: Renal Failurementioning

confidence: 99%

See 3 more Smart Citations

Antihypertensive Medications and Anemia

Sica

Mannino

2007

J of Clinical Hypertension

View full text Add to dashboard Cite

show abstract

Antihypertensive treatment for kidney transplant recipients

Cross

Webster

Masson

et al. 2009

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

BackgroundIn some nontransplant populations, e ects of di erent antihypertensive drug classes vary. Relative e ects in kidney transplant recipients are uncertain. ObjectivesTo assess comparative e ects of di erent classes of antihypertensive agents in kidney transplant recipients. Search methodsMEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, conference proceedings and reference lists of identified studies were searched. Selection criteriaRandomised controlled trials of any antihypertensive agent applied to kidney transplant recipients for at least two weeks were included. Data collection and analysisData was extracted by two investigators independently. Study quality, transplant outcomes and other patient centred outcomes were assessed using random e ects meta-analysis. Risk ratios (RR) for dichotomous outcomes and mean di erence (MD) for continuous outcomes, both with 95% confidence intervals (CI) were calculated. Stratified analyses and meta-regression were used to investigate heterogeneity. Main resultsWe identified 60 studies, enrolling 3802 recipients. Twenty-nine studies (2262 participants) compared calcium channel blockers (CCB) to placebo/no treatment, 10 studies (445 participants) compared angiotensin converting enzyme inhibitors (ACEi) to placebo/no treatment and seven studies (405 participants) compared CCB to ACEi. CCB compared to placebo/no treatment (plus additional agents in either arm as required) reduced gra loss (RR 0.75, 95% CI 0.57 to 0.99) and improved glomerular filtration rate (GFR), (MD, 4.45 mL/min, 95% CI 2.22 to 6.68). Data on ACEi versus placebo/no treatment were inconclusive for GFR (MD -8.07 mL/min, 95% CI -18.57 to 2.43), and variable for gra loss, precluding meta-analysis. In direct comparison with CCB, ACEi decreased GFR (MD -11.48 mL/min, 95% CI -5.75 to -7.21), proteinuria Antihypertensive treatment for kidney transplant recipients (Review)

show abstract

Unerwünschte Arzneimittelwirkungen und Wechselwirkungen von AT1-Rezeptorantagonisten

Schräder

Lüders²

1999

Angiotensin II AT1-Rezeptorantagonisten

View full text Add to dashboard Cite

Losartan versus ramipril in the treatment of postrenal transplant erythrocytosis

Cited by 14 publications

References 3 publications

Antihypertensive Medications and Anemia

Antihypertensive Medications and Anemia

Antihypertensive treatment for kidney transplant recipients

Unerwünschte Arzneimittelwirkungen und Wechselwirkungen von AT1-Rezeptorantagonisten

Contact Info

Product

Resources

About